Aradigm Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquin™ in Patients with Non-Cystic Fibrosis …

Aradigm Corporation today announced that the Company’s Investigational New Drug Application to conduct a pivotal Phase 3 clinical trial of Pulmaquin in non-cystic fibrosis bronchiectasis has been cleared by the U.S.

Leave a Reply

Your email address will not be published. Required fields are marked *